Literature DB >> 26819675

Potent Small Agonists of Protease Activated Receptor 2.

Mei-Kwan Yau1, Jacky Y Suen1, Weijun Xu1, Junxian Lim1, Ligong Liu1, Mark N Adams2, Yaowu He2, John D Hooper2, Robert C Reid1, David P Fairlie1.   

Abstract

Many proteases cut the PAR2 N-terminus resulting in conformational changes that activate cells. Synthetic peptides corresponding to newly exposed N-terminal sequences of PAR2 also activate the receptor at micromolar concentrations. PAR2-selective small molecules reported here induce PAR2-mediated intracellular calcium signaling at nanomolar concentrations (EC50 = 15-100 nM, iCa(2+), CHO-hPAR2 cells). These are the most potent and efficient small molecule ligands to activate PAR2-mediated calcium release and chemotaxis, including for human breast and prostate cancer cells.

Entities:  

Keywords:  Protease activated receptor 2; agonist; cyclohexylglycine; structure−activity relationships

Year:  2015        PMID: 26819675      PMCID: PMC4716605          DOI: 10.1021/acsmedchemlett.5b00429

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

2.  Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.

Authors:  Silvio Antoniak; Mauricio Rojas; Denise Spring; Tara A Bullard; Edward D Verrier; Burns C Blaxall; Nigel Mackman; Rafal Pawlinski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-19       Impact factor: 8.311

3.  Novel agonists and antagonists for human protease activated receptor 2.

Authors:  Grant D Barry; Jacky Y Suen; Giang T Le; Adam Cotterell; Robert C Reid; David P Fairlie
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

Review 4.  Structure, function and pathophysiology of protease activated receptors.

Authors:  Mark N Adams; Rithwik Ramachandran; Mei-Kwan Yau; Jacky Y Suen; David P Fairlie; Morley D Hollenberg; John D Hooper
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

5.  Antagonism of protease-activated receptor 2 protects against experimental colitis.

Authors:  Rink-Jan Lohman; Adam J Cotterell; Jacky Suen; Ligong Liu; Anh T Do; David A Vesey; David P Fairlie
Journal:  J Pharmacol Exp Ther       Date:  2011-10-25       Impact factor: 4.030

6.  A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis.

Authors:  Kristina K Hansen; Philip M Sherman; Laurie Cellars; Patricia Andrade-Gordon; Zhengying Pan; Amos Baruch; John L Wallace; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

7.  Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Authors:  Luis R Gardell; Jian-Nong Ma; Jimmi Gerner Seitzberg; Anne E Knapp; Hans H Schiffer; Ali Tabatabaei; Christopher N Davis; Michelle Owens; Bryan Clemons; Kenneth K Wong; Birgitte Lund; Norman R Nash; Yan Gao; Jelveh Lameh; Kara Schmelzer; Roger Olsson; Ethan S Burstein
Journal:  J Pharmacol Exp Ther       Date:  2008-09-03       Impact factor: 4.030

8.  Toward drugs for protease-activated receptor 2 (PAR2).

Authors:  Mei-Kwan Yau; Ligong Liu; David P Fairlie
Journal:  J Med Chem       Date:  2013-07-30       Impact factor: 7.446

9.  Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration.

Authors:  S Su; Y Li; Y Luo; Y Sheng; Y Su; R N Padia; Z K Pan; Z Dong; S Huang
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

10.  Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist.

Authors:  Sarina B Elmariah; Vemuri B Reddy; Ethan A Lerner
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

View more
  6 in total

1.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

2.  High Affinity Fluorescent Probe for Proteinase-Activated Receptor 2 (PAR2).

Authors:  Jordan C LeSarge; Pierre Thibeault; Mark Milne; Rithwik Ramachandran; Leonard G Luyt
Journal:  ACS Med Chem Lett       Date:  2019-06-06       Impact factor: 4.345

3.  Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.

Authors:  Mark W Majewski; Disha M Gandhi; Trudy Holyst; Zhengli Wang; Irene Hernandez; Ricardo Rosas; Jieqing Zhu; Hartmut Weiler; Chris Dockendorff
Journal:  RSC Med Chem       Date:  2020-07-09

Review 4.  Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection.

Authors:  Rebecca A Rosero; Gabriel J Villares; Menashe Bar-Eli
Journal:  Front Genet       Date:  2016-06-15       Impact factor: 4.599

5.  The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Authors:  Charlotte Avet; Claudio Sturino; Sébastien Grastilleur; Christian Le Gouill; Meriem Semache; Florence Gross; Louis Gendron; Youssef Bennani; Joseph A Mancini; Camil E Sayegh; Michel Bouvier
Journal:  Commun Biol       Date:  2020-11-27

6.  Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy.

Authors:  Marinel Ocasio-Rivera; Frances Marin-Maldonado; Geraline Trossi-Torres; Angely Ortiz-Rosado; Valerie Rodríguez-Irizarry; Eric Rodriguez-Lopez; Sahayra Martínez; Sharilyn Almodóvar; Edu Suarez-Martínez
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.